VPTDF - Ventripoint Makes Application to Amend Warrrants
(TheNewswire)
Toronto, Ontario - The Newswire - October 09, 2020 -Ventripoint Diagnostics Ltd. (" Ventripoint " orthe " Company "), (TSXV:VPT ) ( OTC:VPTDF) announces that it has made an application to the TSX Venture Exchange(the "TSXV") to amend the exercise price of common share purchase warrants originally issued on October2, 2019.
An aggregate of 4,687,132 million warrants wereinitially issued at an exercise price of $0.175 per common share inconnection with a private placement financing (see News Release on Oct2, 2019). Ventripoint intends to amend the exercise price of thewarrants from $0.175 to $0.115 per share. All other provisions of thewarrants will remain the same and all warrants will still expire onOctober 2, 2022.
The warrant repricing is subject to final acceptance byTSXV Exchange.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Mr . Peter Weichler,Director
Email :peter@weichler.ca
Or
Mr. Clay Chase
Email: cc@sdthc.com
Phone: 858-456-7300
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions madeby the Company. Although the Company believes that the expectationsand assumptions on which such forward-looking statements andinformation are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCompany can give no assurance that they will prove to becorrect.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2020 TheNewswire - All rights reserved.